ReviewFrontiers in immunology2022
Insights into
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- Generation and Evaluation of a Multi-Epitope Vaccine AgainstVaccines · 2026Article
- Evaluating a pathogen-specific IgG binding assay for rapid detection of healthcare-associated infections.Scientific reports · 2026Article
- Identification, resistance mechanisms, and innovative therapeutic approaches againstFrontiers in microbiology · 2026Review
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- Immune Delay, Beyond Immune Evasion, as a Driver of Pathogen Propagation Competence Through Neutrophil Dysregulation, to be Mitigated by Low-Frequency Electromagnetic Fields (LF-EMF).International journal of molecular sciences · 2025Review
- Sand fly gut microbiota in Leishmania transmission: roles, interactions, and paratransgenic prospects.Archives of microbiology · 2025Review
- Synthesis of disaccharide and trisaccharide substructures of an A. baumannii lipooligosaccharide core.Carbohydrate research · 2025Article
- In silico screening of epitopes as potential vaccine candidates against pathogenic Acinetobacter baumannii.Genes & genomics · 2025Article
- mRNA-LNP Vaccines Targeting SmpA-PLD and OmpK-Omp22 Induce Protective Immunity AgainstVaccines · 2025Article
- Investigation of the in vitro antimicrobial activity of eravacycline alone and in combination with various antibiotics against MDR Acinetobacter baumanni strains.BMC microbiology · 2025Article
- Multidrug resistantCurrent research in microbial sciences · 2025Review
- Development of a multi-epitope vaccine against Acinetobacter baumannii: A comprehensive approach to combating antimicrobial resistance.PloS one · 2025Article
- Inserting Omp22 into the flagellin protein, replacing its hypervariable region, results in stronger protection against lethal Acinetobacter baumannii infection.Scientific reports · 2024Article
- SPECT Imaging ofPharmaceutics · 2024Article
- Treatment and Management ofInfection and drug resistance · 2024Review
- Effectors of the Type VI Secretion System Have the Potential to Be Modified into Antimicrobial Peptides.Microbiology spectrum · 2023Article
- Epitope mapping ofHeliyon · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.